The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Investigating the impact of pacritinib on survival in patients with MF and severe thrombocytopenia
Aaron Gerds, MD, MS, Cleveland Clinic, Cleveland, OH, discusses the rationale behind conducting analyses to assess the impact of pacritinib on transfusion dependence in patients with myelofibrosis (MF) with severe thrombocytopenia. Transfusion dependence has been identified as an adverse prognostic factor in this patient population, predicting for poorer survival outcomes. By analyzing data from randomized clinical trials such as PERSIST -2, Dr Gerds hopes to identify whether an improvement in anemia and transfusion burden as a result of pacritinib administration will translate to improved survival in patients. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
